Indeed, a number of studies have shown that SIRT1 is a putative oncogene and targeting SIRT1 is effective in inhibiting tumor growth and progression of liver cancer and chronic myeloid leukemia among others [13, 36, 37]. This evidence concerns the gene SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive.